Newly approved drug for Waldenstrom's Macroglobulinemia shows sustained benefit for 2 years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.



from The Medical News http://ift.tt/1NYSlIj